BBIO Earnings Date: Feb 23, 2027 (Estimated) — BridgeBio Pharma, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is BBIO's next earnings date?
BridgeBio Pharma, Inc. (BBIO) is expected to report Q4 2026 earnings on Tuesday, February 23, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.44 on revenue of $318.3M.
How did BBIO do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), BridgeBio Pharma, Inc. posted EPS of -$0.42 versus the -$0.54 estimate, a beat of 22.5%. Revenue was $353.2M against a $293.5M estimate.
How much does BBIO stock move after earnings?
BBIO beat EPS estimates in 2 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 3.5% (up or down) in the day after earnings.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
🤖 AI Earnings Analysis
BridgeBio’s Attruby launch is the clear catalyst: U.S. product revenue rose $145 million year over year to $253.2 million, driving total revenue to $353 million. Strong commercial traction beat estimates, though losses remain substantial at $145 million operating income.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | -0.54 | -0.42 | +22.54% | $353.2M | ✅ Beat | — | — | — |
| 2026-08-10 | Q2 2026 | -0.58 | -0.78 | -32.20% | $243.7M | ❌ Miss | -1.15% | -5.65% | -10.15% |
| 2026-05-07 | Q1 2026 | -0.63 | -0.84 | -33.33% | $194.5M | ❌ Miss | -0.09% | +3.28% | -0.12% |
| 2026-02-24 | Q4 2025 | -0.67 | -1.00 | -49.25% | $154.2M | ❌ Miss | -2.59% | -5.53% | +4.83% |
| 2025-10-29 | Q3 2025 | -0.82 | -0.95 | -15.85% | $120.7M | ❌ Miss | -4.88% | -5.94% | +8.09% |
| 2025-08-05 | Q2 2025 | -0.68 | -0.95 | -39.71% | $110.6M | ❌ Miss | -8.94% | -0.24% | +5.32% |
| 2025-02-20 | Q4 2024 | -1.09 | -1.40 | -28.44% | $5.9M | ❌ Miss | +1.42% | -7.83% | -6.56% |
| 2024-11-12 | Q3 2024 | -0.98 | -0.86 | +12.24% | $2.7M | ✅ Beat | -5.74% | -14.43% | +10.95% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $353.2M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 71.7% | $253.3M | +134.3% | — | — | $108.1M | $254.3M |
| License and Service | 22.5% | $79.3M | +854.3% | — | — | $8.3M | $120.0M |
| Royalty | 5.8% | $20.5M | +379.5% | — | — | $4.3M | $7.1M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.